. Author manuscript; available in PMC: 2021 Jul 13.

Published in final edited form as: Nat Rev Cancer. 2021 Mar 17;21(5):313–324. doi: 10.1038/s41568-021-00340-6

Table 2.

Active clinical trials with FAK inhibitor combinations.

Compound	Clinical trials	Cancer type	Combination agents	Molecular targets
Defactinib (VS-6063) (PF-04554878)	NCT02546531 (Phase I)⁹³	Solid Tumours / Advanced Solid Tumours Pancreatic Cancer	Pembrolizumab / gemcitabine	PD-1
	NCT02758587 (Phase I/IIA)⁹⁰	Non-Small Cell Lung Carcinoma, Mesothelioma, Pancreatic Neoplasms	Pembrolizumab	PD-1
	NCT03287271 (Phase I/II)⁶⁷	Ovarian Cancer	Paclitaxel and carboplatin	-
	NCT03727880 (Phase II)⁹¹	Pancreatic Ductal Adenocarcinoma	Pembrolizumab	PD-1
	NCT03875820 (Phase I)¹²⁴	Advanced RAS mutant solid tumours; Non-Small Cell Lung Carcinoma, Low Grade Serous Ovarian Cancer, Colorectal Cancer, other RAS mutant solid tumours.	VS-6766	MEK/RAF
	NCT04201145 (Phase Ia-Ib)⁹²	Malignant Pleural Mesothelioma	Pembrolizumab	PD-1
	NCT04620330 (Phase II)¹²⁶	Non-Small Cell Lung Cancer with a KRAS Activating Mutation	VS-6766	MEK/RAF
	NCT04625270 (Phase II)¹²⁵	Ovarian Cancer	VS-6766	MEK/RAF
	NCT04331041 (Phase II)¹²⁹	Pancreatic Cancer	Radiotherapy	-
IN10018 (BI 853520)	NCT04109456 (Phase Ib)¹²⁷	Metastatic uveal melanoma or cutaneous NRAS-mutant melanoma	Cobimetinib	MEK